July 12 - 13, 2019 | Hilton Beirut Habtoor Grand - Lebanon

Organized by The Lebanese Society of Medical Oncology
Licensed by The American Society of Clinical Oncology

www.lsmo-lb.org
Friday July 12, 2019

08:00                      REGISTRATION

09:00 - 10:00   Lung Cancer | Non-Small Cell Local-Regional / Small Cell / Thoracic Cancers
Speakers: TBA
Chairs: TBA
- **Abstract 8503**: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
  (David J. Kwiatkowski, MD, PhD) *Presented by Arafat Tufaily MD*

- **Abstract 8504**: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
  (Tina Cascone, MD, PhD) *Presented by Arafat Tufaily MD*

- **Abstract 8506**: Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
  (Luis G. Paz-Ares, MD, PhD) *Presented by Fadi Karak MD*

Lung Cancer | Non-Small Cell Metastatic
Speakers: TBA
Chairs: TBA
- **Abstract 9000**: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).
  (Kazuhiko Nakagawa, MD, PhD) *Presented by Fadlo Khuri MD*

- **Abstract 9001**: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).
  (Vanita Noronha) *Presented by Fadlo Khuri MD*

- **Abstract 9002**: ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
  (Suresh S. Ramalingam, MD) *Presented by Fadlo Khuri MD*
### Friday July 12, 2019

**10:00 - 10:30  Head and Neck Cancer**

**Speakers:** TBA  
**Chairs:** TBA  

- **Abstract 6000:** Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).  
  *(Danny Rischin)*  
  **Presented by Marcel Massoud MD**

- **Abstract 6002:** TPEXtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).  
  *(Joel Guigay, MD)*  
  **Presented by Fadi Karak MD**

- **Abstract 6003:** Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.  
  *(Jun Ma)*  
  **Presented by Ziad Salem MD**

**10:30 - 11:00  Coffee Break**

**11:00 - 11:30  Sarcoma**

**Speakers:** TBA  
**Chairs:** TBA  

- **Abstract LBA3:** ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).  
  *(William D. Tap, MD)*  
  **Presented by Hazem Assi MD**

- **Abstract 11001:** STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.  
  *(Sylvie Bonvalot, MD, PhD)*  
  **Presented by Caroline Semaha MD**

- **Abstract 11015:** Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.  
  *(Melissa Amber Burgess, MD)*  
  **Presented by Rabih Said MD**
### Friday July 12, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:50</td>
<td>Central Nervous System Tumors</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong> TBA</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> TBA</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract 2000:</strong> Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. <em>(Martin J. Van Den Bent, MD, PhD)</em> <strong>Presented by Hampig Kourie MD</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Abstract 2001:</strong> Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial. <em>(Carmen Balana, MD, PhD)</em> <strong>Presented by Francois Kamar</strong></td>
</tr>
<tr>
<td>12:00 - 12:45</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>
Friday July 12, 2019

**14:00 - 15:00 Hematologic Malignancies, Part I**
Leukemia, Myelodysplastic Syndromes, and Allotransplant

Speakers: TBA
Chairs: TBA

- **Abstract 7000**: Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.
  (Mark J. Levis, MD, PhD) *Presented by Ahmad Ibrahim MD*

- **Abstract 7005**: ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).
  (Timothy P. Hughes) *Presented by Joseph Makdessi MD*

---

**Hematologic Malignancies, Part I**
Lymphoma and Chronic Lymphocytic Lymphoma

Speakers: TBA
Chairs: TBA

- **Abstract 7502**: Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD−) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.
  (Kirsten Fischer, MD) *Presented by Fadi Nasr MD*

- **Abstract 7506**: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
  (Nathan Hale Fowler) *Presented by Khaled Ibrahim MD*

- **Abstract 7510**: Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
  (Paul M. Barr, MD) *Presented by Fadi Nasr MD*
### Friday July 12, 2019

**15:00 - 15:40 Hematologic Malignancies, Part II | Plasma Cell Dyscrasia**

**Speakers:** TBA  
**Chairs:** TBA

- **Abstract 8001:** E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.  
  *(Sagar Lonial, MD)* Presented by Ahmad Ibrahim MD

- **Abstract 8004:** A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).  
  *(Paul G. Richardson, MD)* Presented by Khaled Ibrahim MD

- **Abstract 8005:** Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.  
  *(Maria-Victoria Mateos, PhD)* Presented by Nabil Chamseddine MD

- **Abstract 7507:** Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.  
  *(Pieternella J. Lugtenburg)* Presented by Joseph Makdessi MD

**15:40 - 16:00 Coffee Break**

**16:00 - 16:20 Symptoms and Survivorship**

**Speakers:** TBA  
**Chairs:** TBA

- **Abstract 11503:** A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.  
  *(Hironobu Hashimoto, BPharm)* Presented by Georges Chahine MD

- **Abstract 11506:** Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.  
  *(Matteo Lambertini, MD)* Presented by Ahmad Awada MD
## Friday July 12, 2019

### 16:20 - 17:10  Melanoma/Skin Cancers

**Speakers:** TBA  
**Chairs:** TBA

- **Abstract 2512:** Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.  
  *(Alexander M. M. Eggermont, MD)* **Presented by Marwan Ghosn MD**

- **Abstract 9500:** Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).  
  *(Gerald Fogarty, MD)* **Presented by Georges Farha MD**

- **Abstract 9501:** Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).  
  *(Hussein Abdul-Hassan Tawbi, MD, PhD)* **Presented by Marwan Ghosn MD**

- **Abstract 9503:** Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).  
  *(Alexander M. Menzies, MBBS, FRACP, PhD)* **Presented by Wassim Mouchayleh MD**

- **Abstract 9507:** Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.  
  *(Paul D. Nathan, MD)* **Presented by Georges Chahine MD**
Saturday July 13, 2019

09:00 - 09:30  Genitourinary Cancers, PART I | Genitourinary (Prostate) Cancer

Speakers: TBA
Chairs: TBA

- Abstract LBA2: Overall survival (OS) results of a phase III randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co-operative group trial.
  (Christopher Sweeney) Presented by Joseph Makdessi MD

- Abstract 5006: First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
  (Kim N. Chi, MD, FRCPC) Presented by Nizar Bitar MD

- Abstract 5008: Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
  (Michael J. Morris, MD) Presented by Deborah Mukherji MD

09:30 - 10:10  Genitourinary Cancers, PART II | Genitourinary (NonProstate) Cancer

Speakers: TBA
Chairs: TBA

- Abstract 4500: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
  (Brian I. Rini, MD, FACP) Presented by Deborah Mukherji MD

- Abstract 4503: CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
  (Jonathan E. Rosenberg, MD) Presented by Roger Khater MD

- Abstract 4504: Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
  (Matt D. Galsky, MD, FASCO) Presented by Joseph Kattan MD

- Abstract 4505: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
  (Daniel Peter Petrylak, MD) Presented by Joseph Kattan MD
Saturday July 13, 2019

**10:10 - 11:25**  
**Breast Cancer | Local / Regional / Adjuvant**

Speakers: TBA  
Chairs: TBA

- **Abstract 503**: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.  
  *(Joseph A. Sparano, MD)*  
  *Presented by Ahmad Awada MD*

- **Abstract 504**: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GiM).  
  *(Lucia Del Mastro, MD)*  
  *Presented by Ghazi Nsouli MD*

- **Abstract 508**: Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.  
  *(Patricia A. Ganz, MD, FASCO)*  
  *Presented by Fares Azouri MD*

**Breast Cancer | Metastatic**

Speakers: TBA  
Chairs: TBA

- **Abstract 1000**: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).  
  *(Hope S. Rugo, MD, FASCO)*  
  *Presented by Nagi El Saghir MD*

- **Abstract 1002**: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.  
  *(Cristina Saura, MD, PhD)*  
  *Presented by Ahmad Awada MD*

- **Abstract 1003**: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).  
  *(Peter Schmid, MD, PhD, FCRP)*  
  *Presented by Walid Moukaddem MD*

- **Abstract LBA1008**: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.  
  *(Sara A. Hurvitz, MD)*  
  *Presented by Hazem Assi MD*

**11:25 - 11:45**  
**Coffee Break**
Saturday July 13, 2019

11:45 - 12:55  **Gastrointestinal Cancers | Gastrointestinal (Colorectal) Cancer**

Speakers: Ghassan Abou Alfa, MD - Eileen O’reilly, MD

Chairs: TBA

- **Abstract 3501:** Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months (m)) for patients (pts) with high-risk stage II colorectal cancer (CC).
  
  (Timothy Iveson, MD, FRCP) **Presented by Sally Tamraz MD**

- **Abstract 3504:** FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
  
  (Matthew T. Seymour, MD) **Presented by Ghassan Abou Alfa MD**

- **Abstract 3508:** Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.
  
  (Chiara Cremolini, MD) **Presented by Eileen O’Reilly MD**

**Gastrointestinal Cancers | Gastrointestinal (Noncolorectal) Cancer**

Speakers: TBA

Chairs: TBA

- **Abstract LBA4:** Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
  
  (Hedy L. Kindler) **Presented by Eileen O’Reilly MD**

- **Abstract 4000:** APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
  
  (Margaret A. Tempero, MD, FASCO) **Presented by Eileen O’Reilly MD**

- **Abstract 4003:** ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
  
  (Angela Lamarca, MD, PhD) **Presented by Ghassan Abou Alfa MD**

- **Abstract LBA4007:** Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
  
  (Josep Tabernero, MD, PhD) **Presented by Ghassan Abou Alfa MD**
Saturday July 13, 2019

13:00 - 14:00  Lunch Break

14:00 - 15:00  Gynecologic Cancer

Speakers: Muhieddine Seoud, MD & David Atallah, MD

Chairs: TBA

- **Abstract 5500:** A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial. (Matthew A. Powell, MD) *Presented by*

- **Abstract 5505:** Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24. (Mansoor Raza Mirza, MD) *Presented by*

- **Abstract 5506:** Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. (Richard T. Penson, MD, MRCP) *Presented by*

- **Abstract 5508: EWOC-1:** A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. (Claire Falandry) *Presented by*

15:00  Adjourn